The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia
Open accessAbstract
Introduction: To gain a better understanding of the clinical and economic outcomes associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with early onset ventilator-associated pneumonia (VAP), we retrospectively analyzed a multihospital US database to identify patients with VAP over a 24 month period (2002–2003). Method: Data recorded included physiologic, laboratory, culture, and other clinical variables from 59 institutions. VAP was defined as new positive respiratory culture after at least 24 hours of mechanical ventilation (MV) and the presence of primary or secondary ICD-9-CM diagnosis codes of pneumonia. Outcomes measures included in-hospital morbidity and mortality for the population overall and after onset of VAP (duration of MV, intensive care unit [ICU] stay, in-hospital stay, and case mix and severity-adjusted operating cost). The overall cost was calculated at the hospital level using the Center for Medicare and Medicaid Services Cost/Charge Index for each calendar year. Results: A total of 499 patients were identified as having VAP. S. aureus was the leading organism (31% of isolates). Patients with MRSA were significantly older than patients with methicillin-sensitive Staphylococcus aureus (MSSA; median age 74 versus 67 years, P < 0.05) and more likely to be medical patients. Compared with MSSA patients, MRSA patients on average consumed excess resources of 4.4 (95% confidence interval 0.6–8.2) overall MV days, 3.8 (-0.5 to +8.0) days of inpatient length of stay (LOS), 5.3 (1.0–9.7) ICU days, and US$7731 (-US$8393 to +US$23,856) total cost after controlling for case mix and other factors. Furthermore, MRSA patients needed excess resources after the onset of VAP (4.5 [95% confidence interval 1.0–8.1] MV days, 3.7 [-0.5 to +8.0] inpatient days, and 4.4 [0.4–8.4] ICU days) after controlling for the same case mix and admission severity covariates. Conclusion: S. aureus remains a common cause of VAP. VAP due to MRSA was associated with increased overall LOS, ICU LOS, and attributable ICU LOS compared with MSSA-related VAP. Although not statistically significant because of small sample size and large variation, the attributable excess costs of MRSA amounted to approximately US$8000 per case after controlling for case mix and severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcomes of Health-care–Associated Pneumonia
Kollef, M. H., Shorr, A., Tabak, Y. P., Gupta, V., Liu, L. Z., & Johannes, R. S. (2005) · Chest · doi:10.1378/chest.128.6.3854 · Cited by 948
Self-citation
Research works printed but not linked: 24
- Safdar N, Dezfulian C, Collard HR, Saint S: Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005, 33: 2184-2193. 10.1097/01.CCM.0000181731.53912.D9 · DOI · Paper page
- Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C: The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159: 1249-1256. · DOI · Paper page
- Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122: 2115-2121. 10.1378/chest.122.6.2115 · DOI · Paper page
- Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ: Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31: 1312-1317. 10.1097/01.CCM.0000063087.93157.06 · DOI · Paper page
- Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D: Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004, 25: 1090-1096. 10.1086/502349 · DOI
- Chastre J, Fagon J-Y: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165: 867-903. · DOI · Paper page
- Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, McGowan JE: Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002, 8: 697-701. · DOI
- Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y: Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36: 53-59. 10.1086/345476 · DOI · Paper page
- Zahar J-R, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, Lassence AD, Descorps-Declere A, Adrie C, Costa de Beauregard M-A, et al.: Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005, 41: 1224-1231. 10.1086/496923 · DOI
- Combes A, Luyt CE, Fagon JY, Wollf M, Trouillet JL, Gibert C, Chastre J: Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004, 170: 786-792. 10.1164/rccm.200403-346OC · DOI
- Ewig S, Torres A: Prevention and management of ventilator-associated pneumonia. Curr Opin Crit Care 2002, 8: 58-69. 10.1097/00075198-200202000-00010 · DOI
- Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y: The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26: 166-174. 10.1086/502522 · DOI · Paper page
- Abramson MA, Sexton DJ: Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999, 20: 408-411. 10.1086/501641 · DOI · Paper page
- Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36: 592-598. 10.1086/367653 · DOI · Paper page
- Iezzoni LI, Ash AS, Coffman GA, Moskowitz MA: Admission and mid-stay MedisGroups scores as predictors of hospitalization charges. Med Care 1991, 29: 210-220. 10.1097/00005650-199103000-00003 · DOI
- Iezzoni LI, Moskowitz MA: A clinical assessment of MedisGroups. JAMA 1988, 260: 3159-3163. 10.1001/jama.260.21.3159 · DOI
- Silber JH, Rosenbaum PR, Schwartz JS, Ross RN, Williams SV: Evaluation of the complication rate as a measure of quality of care in coronary artery bypass graft surgery. JAMA 1995, 274: 317-323. 10.1001/jama.274.4.317 · DOI · Paper page
- Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336: 243-250. 10.1056/NEJM199701233360402 · DOI · Paper page
- Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Smulders M, Lapetina E, Gemmen E: The burden of Staphylococcus aureus infections on hospitals in the United States. An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005, 165: 1756-1761. 10.1001/archinte.165.15.1756 · DOI · Paper page
- Shorr AF, Combes A, Kollef MH, Chastre J: Methicillin resistant Staphylococcus aureus prolongs intensive care unit length of stay in ventilator-associated pneumonia despite initially appropriate antibiotic therapy. Crit Care Med 2006, 34: 700-706. 10.1097/01.CCM.0000201885.57697.21 · DOI
- Olson ME, Harmon BG, Kollef MH: Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs. Chest 2002, 121: 863-870. 10.1378/chest.121.3.863 · DOI · Paper page
- Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ: Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003, 47: 1589-1597. 10.1128/AAC.47.5.1589-1597.2003 · DOI · Paper page
- Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr M: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003, 24: 362-386. 10.1086/502213 · doi:10.1086/502213 · Paper page
- Puzniak LA, Leet T, Mayfield J, Kollef MH, Mundy LM: To gown or not to gown: the effect on acquisition of vancomycin resistant enterococci. Clin Infect Dis 2002, 35: 18-25. 10.1086/340739 · DOI
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Köck, R., Becker, K., Cookson, B., van Gemert-Pijnen, J. E., Harbarth, S., Kluytmans, J., Mielke, M., Peters, G., Skov, R. L., Struelens, M. J., et al. (2010) · Eurosurveillance · doi:10.2807/ese.15.41.19688-en · Cited by 611
Lambert, M.-L., Suetens, C., Savey, A., Palomar, M., Hiesmayr, M., Morales, I., Agodi, A., Frank, U., Mertens, K., Schumacher, M., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70258-9 · Cited by 443
Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., & Menon, V. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-32 · Cited by 344
Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review
Zhen, X., Lundborg, C. S., Sun, X., Hu, X., & Dong, H. (2019) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-019-0590-7 · Cited by 337
Metadata
- Authors
- Shorr, A. F., Tabak, Y. P., Gupta, V., Johannes, R., Liu, L. Z., & Kollef, M. H.
- Venue
- Critical Care
- Published
- 2006-06-29
- Volume
- 10
- Issue
- 3
- Pages
- R97-R97
- ISSN
- 1364-8535 (ISSN-L)
- OpenAlex
- W2024937400
- Cited by
- 160
- References
- 1
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. https://app.cochat.ai/papers/10.1186/cc4934
- The paper
- Shorr, A. F., Tabak, Y. P., Gupta, V., Johannes, R., Liu, L. Z., & Kollef, M. H. (2006). Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Critical Care. https://doi.org/10.1186/cc4934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.